Therapeutics News

Proposed legislation in Wyoming would allow certain noninvasive procedures within the optometry scope of practice as well as the ability to prescribe, dispense and administer approved pharmaceutical agents.

With all of the attention currently placed on prescription drug prices, it’s difficult to believe that a major retail distributor of medications would do anything but toe the proverbial line when it comes to sales practices. However, last month, Walgreens was ordered to pay more than $270 million for improperly billing Medicare, Medicaid and other state- and federal-level programs over the course of 10 years.

Okogen initiated its phase 2 clinical trial, RUBY, for OKG-0301, a topical ophthalmic formulation of ranpirnase, in patients with acute adenoviral conjunctivitis.

The Trump Administration proposed a new rule last week to lower prices of prescription drugs and out-of-pocket costs by encouraging manufacturers to offer direct discounts to patients, according to a press release issued by HHS.

More than 90% of physicians reported prior authorization requirements had a negative impact on patient clinical outcomes and that prior authorization procedures held up patient access to necessary care, according a new AMA survey.

In 2018, after President Donald Trump publicly condemned the pharmaceutical industry for skyrocketing prescription drug prices, several of the largest drug manufacturers — including Merck, Novartis, Pfizer and Roche — announced a series of temporary price freezes to their brand-name medications.

In December, Primary Care Optometry News quoted me in an article about central serous chorioretinopathy. The article talked about a lot of facets of the disease, and one of them was a new oral treatment with eplerenone.

SAN ANTONIO – Biologic agents are an important new class of medications available for treating noninfectious uveitis, David K. Scales, MD, said here at the Anterior Segment Section Symposium during the American Academy of Optometry meeting.

Latanoprost was identified as the most common medication prescribed by ophthalmologists and optometrists in a review of nationwide Medicare Part D claims of ocular hypotensive medications.

OcuMedic Inc. announced that its contact lens drug delivery system has been granted a patent by the European Patent Office.